UROGEN PHARMA LTD (URGN)
Health Care · Uro-oncology and specialty cancer therapeutics · NASDAQ
Urogen Pharma commercializes RTGel hydrogel-based therapies and newly-approved mitomycin treatments for non-surgical bladder and upper urinary tract cancer management.
What UROGEN PHARMA LTD does
Urogen Pharma is a biotechnology company focused on developing and commercializing treatments for urothelial and specialty cancers. The company has developed RTGel, a proprietary reverse-thermal hydrogel technology that enables sustained drug release in the urinary tract. It has two FDA-approved products: Jelmyto (mitomycin) for low-grade upper tract urothelial cancer and Zusduri (mitomycin) for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, as well as an investigational oncolytic virus (UGN-501) in its pipeline.
Themes: ["Uro-oncology","Non-muscle invasive bladder cancer (NMIBC)","Upper tract urothelial cancer (UTUC)","Non-surgical cancer treatment","Oncolytic virus immunotherapy","Drug delivery technology"]
Fundamentals
- Price$40.23 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+191.3% as of 2026-07-09 close
- Net margin-94.8% as of 2026-07-10
- Gross margin+89.8% as of 2026-07-10
- ROE-204.5% as of 2026-07-10
- Debt / equity4.77 as of 2026-07-10
- Revenue growth (YoY)+52.9% as of 2026-07-10
- Revenue CAGR (3y)+19.5% SEC XBRL
- Beta1.53 as of 2026-07-10
Key risks (from latest filing)
["Commercial execution risk for newly approved Zusduri—success depends on rapid market adoption against established TURBT surgical standard despite favorable positioning as first non-surgical option.","Immuno-uro-oncology pipeline dependency—UGN-501 is investigational and faces uncertain regulatory and clinical development timelines, with limited near-term revenue contribution expected.","Reimbursement and pricing pressure—as a novel treatment for a niche urothelial cancer indication, market access and payer adoption remain uncertain despite the company's large addressable market estimates."]
Competitors & peers
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Astellas Pharma (ASXX)
- Janssen Pharmaceuticals
- Specialty surgical device/oncology companies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.